Jordyn Sava

GEMSTONE-301 showed sugemalimab to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival in patients with unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.

In an interview with Targeted Oncology following the tweet chat, Omid A. Hamid, MD, discussed the key takeaways from the discussion, including the ways he would treat the patient discussed in the case.

A biologics license application has been submitted to the FDA for N-803 plus Bacillus Calmette-Guérin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer in situ with or without Ta or T1 disease.

Melhem Solh, MD, discussed how the post transplantation outcomes for patients with MDS and AML with the TP53 gene mutation have changed to what it is today.

A phase 1b trial of ALRN-6924 in patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel has treated its first patients.

A partial clinical hold has been placed by the FDA on a phase 1 trial examining the use of FHD-286 as treatment for patients with relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome.

Priority review to a biologics license application has been granted by the FDA for mirvetuximab soravtansine to treat patients with folate receptor alpha-high platinum-resistant ovarian cancer.

Continuing to monitor trends will be important in regard to the American Thyroid Association developing other updates to its thyroid cancer treatment guidelines and trends.

The FDA allows for an investigational new drug application for the start of the BEXMAB study of bexmarilimab plus standard of care therapy in various hematologic malignancies.

For military veterans, future research should be accompanied by systematic efforts to improve skin cancer prevention, treatment, and outcomes among military service members and veterans, according to Carolyn J. Heckman, PhD.

In an interview with Targeted Oncology, Nicolas Gazeau, further discusses his analysis of anakinra when administered at 2 different dose regimens for patients with refractory CRS/ICANS after CAR T-cell therapy.

A collaboration between Merck and Athenex, Inc. has been announced to evaluate oraxol plus pembrolizumab in certain patients with non-small cell lung cancer.

Having an antibiotic de-escalation guideline did not affect the rate of bacterial infection after antibiotic de-escalation, all cause-mortality, or hospital length of stay in patients with acute myeloid leukemia and febrile neutropenia who were clinically stable and afebrile.

Data supporting prostate-specific antigen screening shows harm-benefit tradeoff to be more favorable with complementary approaches to quantifying overdiagnosis.

Long-term follow-up results from the JAVELIN Bladder 100 study further support the standard-of-care role of avelumab as frontline maintenance in patients with urothelial carcinoma.

Investigators of the phase 1/2 IMAGINE study, evaluating MT-101 in patients with refractory or relapsed peripheral T-cell lymphoma, have dosed its first patient.

The use of single-agent odronextamab demonstrated a manageable safety profile and promising preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma.

The SKYSCRAPER-01 study missed its co-primary end point of progression-free survival in patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer.

Endocrine therapy plus bevacizumab with the possibility of weekly paclitaxel reinduction signals efficacy and demonstrates a good safety profile in patients with ER-positive, HER2-negative advanced or metastatic breast cancer who have responded to induction therapy.

Breakthrough therapy designation has been granted to repotrectinib by the FDA for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer.

The phase 2 VB C-02 trial examining VB10.16 in combination with atezolizumab demonstrated positive results in patients with HPV16-positive advanced cervical cancer.

Adam Cohen, MD, discussed the recent updates and advancements in BCMA-directed therapies for multiple myeloma.

Production of lutetium Lu 177 vipivotide tetraxetan and Luthathera have been temporarily suspended due to potential quality issues identified in their manufacturing processes.

The phase 2 clinical trial of the combination therapy, GT90001 and nivolumab, for the treatment of patients with advanced hepatocellular carcinoma has dosed its first patient.

The first patient has been enrolled into the PREMIER registry for patients with all stages of cancer.

Increased risks of several solid tumors found to be associated with radioactive iodine treatment for patients with childhood and young-adulthood differentiated thyroid cancer.

The primary end point has been met in the phase 3 ADVANCE trial which evaluated the efficacy and safety of efgartigimod alfa-fcab in patients with thrombocytopenia.

The FDA has granted a fast track designation to HM43239 for the treatment of patients with relapsed or refractory acute myeloid leukemia whose tumors harbor a FLT3 mutation.

Survival rates for patients with different subtypes of early breast cancer who had a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel are promising.

Combination of ribociclib plus fulvestrant achieved a median overall survival of 67.6 months in the first-line setting for patients with postmenopausal, hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.